Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 2
1971 2
1972 1
1973 2
1974 1
1975 1
1976 2
1982 1
1991 1
1995 1
1997 1
1998 1
2001 3
2002 1
2003 2
2004 4
2005 5
2006 3
2007 1
2008 5
2009 4
2010 5
2011 3
2012 4
2013 5
2014 2
2015 1
2017 2
2018 10
2019 9
2020 8
2021 8
2022 10
2023 12
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Results by year

Filters applied: . Clear all
Page 1
Hepatitis B virus infection in children and adolescents.
Indolfi G, Easterbrook P, Dusheiko G, Siberry G, Chang MH, Thorne C, Bulterys M, Chan PL, El-Sayed MH, Giaquinto C, Jonas MM, Meyers T, Walsh N, Wirth S, Penazzato M. Indolfi G, et al. Among authors: chan pl. Lancet Gastroenterol Hepatol. 2019 Jun;4(6):466-476. doi: 10.1016/S2468-1253(19)30042-1. Epub 2019 Apr 11. Lancet Gastroenterol Hepatol. 2019. PMID: 30982722 Review.
Global reporting of progress towards elimination of hepatitis B and hepatitis C.
Cui F, Blach S, Manzengo Mingiedi C, Gonzalez MA, Sabry Alaama A, Mozalevskis A, Séguy N, Rewari BB, Chan PL, Le LV, Doherty M, Luhmann N, Easterbrook P, Dirac M, de Martel C, Nayagam S, Hallett TB, Vickerman P, Razavi H, Lesi O, Low-Beer D. Cui F, et al. Among authors: chan pl. Lancet Gastroenterol Hepatol. 2023 Apr;8(4):332-342. doi: 10.1016/S2468-1253(22)00386-7. Epub 2023 Feb 8. Lancet Gastroenterol Hepatol. 2023. PMID: 36764320
Pharmacokinetics of Oral Nirmatrelvir/Ritonavir, a Protease Inhibitor for Treatment of COVID-19, in Subjects With Renal Impairment.
Toussi SS, Neutel JM, Navarro J, Preston RA, Shi H, Kavetska O, LaBadie RR, Binks M, Chan PLS, Demers N, Corrigan B, Damle B. Toussi SS, et al. Among authors: chan pls. Clin Pharmacol Ther. 2022 Oct;112(4):892-900. doi: 10.1002/cpt.2688. Epub 2022 Jul 5. Clin Pharmacol Ther. 2022. PMID: 35712797 Free PMC article. Clinical Trial.
Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.
Singh RSP, Toussi SS, Hackman F, Chan PL, Rao R, Allen R, Van Eyck L, Pawlak S, Kadar EP, Clark F, Shi H, Anderson AS, Binks M, Menon S, Nucci G, Bergman A. Singh RSP, et al. Among authors: chan pl. Clin Pharmacol Ther. 2022 Jul;112(1):101-111. doi: 10.1002/cpt.2603. Epub 2022 May 4. Clin Pharmacol Ther. 2022. PMID: 35388471 Free PMC article. Clinical Trial.
Hepatitis C virus infection in children and adolescents.
Indolfi G, Easterbrook P, Dusheiko G, El-Sayed MH, Jonas MM, Thorne C, Bulterys M, Siberry G, Walsh N, Chang MH, Meyers T, Giaquinto C, Wirth S, Chan PL, Penazzato M. Indolfi G, et al. Among authors: chan pl. Lancet Gastroenterol Hepatol. 2019 Jun;4(6):477-487. doi: 10.1016/S2468-1253(19)30046-9. Epub 2019 Apr 11. Lancet Gastroenterol Hepatol. 2019. PMID: 30982721 Review.
Drug treatment effects on disease progression.
Chan PL, Holford NH. Chan PL, et al. Annu Rev Pharmacol Toxicol. 2001;41:625-59. doi: 10.1146/annurev.pharmtox.41.1.625. Annu Rev Pharmacol Toxicol. 2001. PMID: 11264471 Review.
120 results